AAAAAA

   
Results: 1-9 |
Results: 9
CLINICAL PHARMACOKINETICS OF PERILLYL ALCOHOL (POH) AND METABOLITES FOLLOWING ORAL DOSING
Authors: CHAN KK ZHANG Z CHEN H GANAPATHI R HAYTON W ELSON P HAWK E KELLOFF G BUDD GT
Citation: Kk. Chan et al., CLINICAL PHARMACOKINETICS OF PERILLYL ALCOHOL (POH) AND METABOLITES FOLLOWING ORAL DOSING, Annals of oncology, 9, 1998, pp. 476-476
EFFECT OF SULINDAC SULFONE ON PROLIFERATION, APOPTOSIS, AND POLYPS INA CLINICAL-TRIAL IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP) WITH RECTAL POLYPS
Authors: VANSTOLK R BUDD GT KRESTY R GANAPATHI R ELSON P CHURCH J PIAZZA G FRYER B PROVENCHER K PAMUKCU R HAWK E KELLOFF G STONER G
Citation: R. Vanstolk et al., EFFECT OF SULINDAC SULFONE ON PROLIFERATION, APOPTOSIS, AND POLYPS INA CLINICAL-TRIAL IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP) WITH RECTAL POLYPS, Gastroenterology, 114(4), 1998, pp. 2881-2881
SELECTIVE APOPTOSIS OF NEOPLASTIC-CELLS ACCOMPANIES POLYP REGRESSION IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP) PATIENTS TREATED WITH FGN-1 (SULINDAC SULFONE) - EVIDENCE FOR A CYCLOOXYGENASE INDEPENDENT MECHANISM
Authors: PIAZZA GA FRYER BH VANSTOLK RU BUDD GT STONER GD HAWK E KELLOFF G PAMUKCU R AHNEN DJ GANAPATHI R
Citation: Ga. Piazza et al., SELECTIVE APOPTOSIS OF NEOPLASTIC-CELLS ACCOMPANIES POLYP REGRESSION IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP) PATIENTS TREATED WITH FGN-1 (SULINDAC SULFONE) - EVIDENCE FOR A CYCLOOXYGENASE INDEPENDENT MECHANISM, Gastroenterology, 112(4), 1997, pp. 638-638
CLINICOPATHOLOGICAL CORRELATION OF RECTAL ADENOMA REGRESSION IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP) TREATED WITH SULINDAC SULFONE IN A PHASE I II TRIAL/
Authors: VANSTOLK RU DEYOUNG B CHURCH JM GANAPATHI R PROVENCHER K STONER G HAWK E PAMUKCU R KELLOFF G BUDD GT
Citation: Ru. Vanstolk et al., CLINICOPATHOLOGICAL CORRELATION OF RECTAL ADENOMA REGRESSION IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP) TREATED WITH SULINDAC SULFONE IN A PHASE I II TRIAL/, Gastroenterology, 112(4), 1997, pp. 673-673
PHASE-I TRIAL OF SULINDAC SULFONE IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP) WITH RECTAL POLYPS - OPTIMAL DOSE AND SAFETY
Authors: VANSTOLK RU BUDD GT HAYTON W ELSON P PROVENCHER K CHURCH JM GANAPATHI R STONER G HAWK E PAMUKCU R KELLOFF G CHAN K
Citation: Ru. Vanstolk et al., PHASE-I TRIAL OF SULINDAC SULFONE IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP) WITH RECTAL POLYPS - OPTIMAL DOSE AND SAFETY, Gastroenterology, 112(4), 1997, pp. 673-673
SURROGATE END-POINT BIOMARKER (SEB) GUIDED DRUG DEVELOPMENT - A PRACTICAL STRATEGY FOR CHEMOPREVENTION (CP) OF PREINVASIVE CANCER (PRECA)
Authors: LIEBERMAN R BOONE C CROWELL J HAWK E MALONE W STEELE V LUBET R SIGMAN C KELLOFF G
Citation: R. Lieberman et al., SURROGATE END-POINT BIOMARKER (SEB) GUIDED DRUG DEVELOPMENT - A PRACTICAL STRATEGY FOR CHEMOPREVENTION (CP) OF PREINVASIVE CANCER (PRECA), Clinical pharmacology and therapeutics, 61(2), 1997, pp. 1-1
RISK BIOMARKERS AND CURRENT STRATEGIES FOR CANCER CHEMOPREVENTION
Authors: KELLOFF GJ BOONE CW CROWELL JA NAYFIELD SG HAWK E MALONE WF STEELE VE LUBET RA SIGMAN CC
Citation: Gj. Kelloff et al., RISK BIOMARKERS AND CURRENT STRATEGIES FOR CANCER CHEMOPREVENTION, Journal of cellular biochemistry, 1996, pp. 1-14
NSAID TRIALS, SPORADIC ADENOMAS, AND CONSERVATIVE INFERENCES
Authors: HAWK E PRINDIVILLE S KELLOFF G
Citation: E. Hawk et al., NSAID TRIALS, SPORADIC ADENOMAS, AND CONSERVATIVE INFERENCES, Gastroenterology, 110(2), 1996, pp. 654-654
STRATEGIES FOR PHASE-II CANCER CHEMOPREVENTION TRIALS - CERVIX, ENDOMETRIUM, AND OVARY
Authors: KELLOFF GJ BOONE CW CROWELL JA NAYFIELD SG HAWK E STEELE VE LUBET RA SIGMAN CC
Citation: Gj. Kelloff et al., STRATEGIES FOR PHASE-II CANCER CHEMOPREVENTION TRIALS - CERVIX, ENDOMETRIUM, AND OVARY, Journal of cellular biochemistry, 1995, pp. 1-9
Risultati: 1-9 |